Intradermal delivery of TLR agonists in a human explant skin model: Preferential activation of migratory dendritic cells by polyribosinic- polyribocytidylic acid and peptidoglycans

Journal of Immunology

Volumn 190, Issue 7, 2013, Pages 3338-3345

  Oosterhoff, Dinja ^a   Heusinkveld, Moniek ^b   Lougheed, Sinéad M ^a   Kosten, Ilona ^a   Lindstedt, Malin ^c   Bruijns, Sven C M ^a   Van Es, Thomas ^a   Van Kooyk, Yvette ^a   Van Der Burg, Sjoerd H ^b   De Gruijl, Tanja D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CD70 ANTIGEN; PEPTIDOGLYCAN; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 2 AGONIST; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CELL MIGRATION; CELL POLARITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DERMIS; EXPLANT; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LANGERHANS CELL; NORMAL HUMAN; PRIORITY JOURNAL; SKIN; T LYMPHOCYTE; TH1 CELL; UPREGULATION;

CELL MOVEMENT; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION MEDIATORS; INJECTIONS, INTRADERMAL; KERATINOCYTES; LANGERHANS CELLS; LIGANDS; PEPTIDOGLYCAN; PHENOTYPE; PHOSPHORYLATION; POLY I-C; SKIN; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 84875426050     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200598     Document Type: Article

References (31)

1. Karbach, J., S. Gnjatic, A. Bender, A. Neumann, E. Weidmann, J. Yuan, C. A. Ferrara, E. Hoffmann, L. J. Old, N. K. Altorki, and E. Jäger. 2010. Tumorreactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int. J. Cancer 126: 909-918.
2. Kenter, G. G., M. J. Welters, A. R. Valentijn, M. J. Lowik, D. M. Berends-van der Meer, A. P. Vloon, F. Essahsah, L. M. Fathers, R. Offringa, J. W. Drijfhout, et al. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361: 1838-1847.
3. Kupper, T. S., and R. C. Fuhlbrigge. 2004. Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. 4: 211-222.
4. Liu, L., Q. Zhong, T. Tian, K. Dubin, S. K. Athale, and T. S. Kupper. 2010. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat. Med. 16: 224-227.
5. van den Hende, M., M. I. van Poelgeest, J. M. van der Hulst, J. de Jong, J. W. Drijfhout, G. J. Fleuren, A. R. Valentijn, A. R. Wafelman, G. M. Slappendel, C. J. Melief, et al. 2008. Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia. Int. J. Cancer 123: 146-152.
6. Duthie, M. S., H. P. Windish, C. B. Fox, and S. G. Reed. 2011. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239: 178-196.
7. Gnjatic, S., N. B. Sawhney, and N. Bhardwaj. 2010. Toll-like receptor agonists: are they good adjuvants? Cancer J. 16: 382-391.
8. van der Aar, A. M., R. M. Sylva-Steenland, J. D. Bos, M. L. Kapsenberg, E. C. de Jong, and M. B. Teunissen. 2007. Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J. Immunol. 178: 1986-1990.
9. Hari, A., T. L. Flach, Y. Shi, and P. R. Mydlarski. 2010. Toll-like receptors: role in dermatological disease. Mediators Inflamm. 2010: 437246.
10. Karim, R., C. Meyers, C. Backendorf, K. Ludigs, R. Offringa, G. J. van Ommen, C. J. Melief, S. H. van der Burg, and J. M. Boer. 2011. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS ONE 6: e17848.
11. Wang, J., K. Hori, J. Ding, Y. Huang, P. Kwan, A. Ladak, and E. E. Tredget. 2011. Toll-like receptors expressed by dermal fibroblasts contribute to hypertrophic scarring. J. Cell. Physiol. 226: 1265-1273.
12. de Gruijl, T. D., C. C. Sombroek, S. M. Lougheed, D. Oosterhoff, J. Buter, A. J. van den Eertwegh, R. J. Scheper, and H. M. Pinedo. 2006. A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance. J. Immunol. 176: 7232-7242.
13. Santegoets, S. J., S. Gibbs, K. Kroeze, R. van de Ven, R. J. Scheper, C. A. Borrebaeck, T. D. de Gruijl, and M. Lindstedt. 2008. Transcriptional profiling of human skin-resident Langerhans cells and CD1a+ dermal dendritic cells: differential activation states suggest distinct functions. J. Leukoc. Biol. 84: 143-151.
14. Chamorro, S., J. J. García-Vallejo, W. W. Unger, R. J. Fernandes, S. C. Bruijns, S. Laban, B. O. Roep, B. A. 't Hart, and Y. van Kooyk. 2009. TLR triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program. J. Immunol. 183: 2984-2994.
15. García-Vallejo, J. J., B. Van Het Hof, J. Robben, J. A. Van Wijk, I. Van Die, D. H. Joziasse, and W. Van Dijk. 2004. Approach for defining endogenous reference genes in gene expression experiments. Anal. Biochem. 329: 293-299.
16. Romani, N., V. Flacher, C. H. Tripp, F. Sparber, S. Ebner, and P. Stoitzner. 2012. Targeting skin dendritic cells to improve intradermal vaccination. Curr. Top. Microbiol. Immunol. 351: 113-138.
17. Peiser, M., J. Koeck, C. J. Kirschning, B. Wittig, and R. Wanner. 2008. Human Langerhans cells selectively activated via Toll-like receptor 2 agonists acquire migratory and CD4+T cell stimulatory capacity. J. Leukoc. Biol. 83: 1118-1127.
18. Jurkin, J., Y. M. Schichl, R. Koeffel, T. Bauer, S. Richter, S. Konradi, B. Gesslbauer, and H. Strobl. 2010. miR-146a is differentially expressed by myeloid dendritic cell subsets and desensitizes cells to TLR2-dependent activation. J. Immunol. 184: 4955-4965.
19. Ouwehand, K., D. Oosterhoff, M. Breetveld, R. J. Scheper, T. D. de Gruijl, and S. Gibbs. 2011. Irritant-induced migration of Langerhans cells coincides with an IL-10-dependent switch to a macrophage-like phenotype. J. Invest. Dermatol. 131: 418-425.
20. Kalali, B. N., G. Köllisch, J. Mages, T. Müller, S. Bauer, H. Wagner, J. Ring, R. Lang, M. Mempel, and M. Ollert. 2008. Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-mediated differential signaling. J. Immunol. 181: 2694-2704.
21. Lai, Y., A. Di Nardo, T. Nakatsuji, A. Leichtle, Y. Yang, A. L. Cogen, Z. R. Wu, L. V. Hooper, R. R. Schmidt, S. von Aulock, et al. 2009. Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nat. Med. 15: 1377-1382.
22. Longhi, M. P., C. Trumpfheller, J. Idoyaga, M. Caskey, I. Matos, C. Kluger, A. M. Salazar, M. Colonna, and R. M. Steinman. 2009. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206: 1589-1602.
23. Farina, G. A., M. R. York, M. Di Marzio, C. A. Collins, S. Meller, B. Homey, I. R. Rifkin, A. Marshak-Rothstein, T. R. Radstake, and R. Lafyatis. 2010. Poly (I:C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J. Invest. Dermatol. 130: 2583-2593.
24. van der Aar, A. M., R. de Groot, M. Sanchez-Hernandez, E. W. Taanman, R. A. van Lier, M. B. Teunissen, E. C. de Jong, and M. L. Kapsenberg. 2011. Cutting edge: virus selectively primes human langerhans cells for CD70 expression promoting CD8+ T cell responses. J. Immunol. 187: 3488-3492.
25. Kobayashi, M., R. Yoshiki, J. Sakabe, K. Kabashima, M. Nakamura, and Y. Tokura. 2009. Expression of toll-like receptor 2, NOD2 and dectin-1 and stimulatory effects of their ligands and histamine in normal human keratinocytes. Br. J. Dermatol. 160: 297-304.
26. Volz, T., M. Nega, J. Buschmann, S. Kaesler, E. Guenova, A. Peschel, M. Röcken, F. Götz, and T. Biedermann. 2010. Natural Staphylococcus aureusderived peptidoglycan fragments activate NOD2 and act as potent costimulators of the innate immune system exclusively in the presence of TLR signals. FASEB J. 24: 4089-4102.
27. Kratky, W., C. Reis e Sousa, A. Oxenius, and R. Spörri. 2011. Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination. Proc. Natl. Acad. Sci. USA 108: 17414-17419.
28. Spörri, R., and C. Reis e Sousa. 2005. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat. Immunol. 6: 163-170.
29. Schneider, L. P., A. J. Schoonderwoerd, M. Moutaftsi, R. F. Howard, S. G. Reed, E. C. de Jong, and M. B. Teunissen. 2012. Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells. Vaccine 30: 4216-4224.
30. Adams, S., D. W. O'Neill, D. Nonaka, E. Hardin, L. Chiriboga, K. Siu, C. M. Cruz, A. Angiulli, F. Angiulli, E. Ritter, et al. 2008. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181: 776-784.
31. Shackleton, M., I. D. Davis, W. Hopkins, H. Jackson, N. Dimopoulos, T. Tai, Q. Chen, P. Parente, M. Jefford, K. A. Masterman, et al. 2004. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 4: 9.